Immunity and the burden of herpes zoster

Journal of Medical Virology

Volumn 86, Issue 3, 2014, Pages 525-530

  Choi, Won Suk ^a   Kwon, Soon Sun ^a   Lee, Jacob ^b   Choi, Su Mi ^c   Lee, Jin Soo ^d   Eom, Joong Sik ^b   Sohn, Jang Wook ^a   Choeng, Hee Jin ^a  

^a Korea University College of Medicine   (South Korea)

^b Hallym University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Inha University School of Medicine   (South Korea)

Author keywords

Disease burden; Herpes zoster; Immunity

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DETERIORATION; FEMALE; HEALTH CARE COST; HERPES ZOSTER; HOSPITALIZATION; HUMAN; IMMUNE STATUS; IMMUNOCOMPROMISED PATIENT; KOREA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROLOGICAL COMPLICATION; UNIVERSITY HOSPITAL;

HERPES ZOSTER;

DISEASE BURDEN; HERPES ZOSTER; IMMUNITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HERPES ZOSTER; HOSPITALIZATION; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; KOREA; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84891925832     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23830     Document Type: Article

References (20)

1. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M. 2008. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 83:472-476.
2. Choi WS, Noh JY, Huh JY, Jo YM, Lee J, Song JY, Kim WJ, Cheong HJ. 2010. Disease burden of herpes zoster in Korea. J Clin Virol 47:325-329.
3. Donahue JG, Choo PW, Manson JE, Platt R. 1995. The incidence of herpes zoster. Arch Intern Med 155:1605-1609.
4. Gershon AA, Gershon MD. 2010. Perspectives on vaccines against varicella-zoster virus infections. Curr Top Microbiol Immunol 342:359-372.
5. Gnann JW Jr, Whitley RJ. 2002. Clinical practice. Herpes zoster N Engl J Med 347:340-346.
6. Harpaz R, Ortega-Sanchez IR, Seward JF. 2008. Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57:1-30, quiz C E32-E34.
7. Hasegawa Y, Kawahara F, Nagai H, Hirose T, Imai Y, Ishiguro T, Chou T. 2009. Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy. Rinsho Ketsueki 50:488-494.
8. Hornberger J, Robertus K. 2006. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 145:317-325.
9. Kanda Y, Mineishi S, Saito T, Saito A, Yamada S, Ohnishi M, Chizuka A, Niiya H, Suenaga K, Nakai K, Takeuchi T, Makimoto A, Tanosaki R, Kami M, Tanaka Y, Fujita S, Watanabe T, Kobayashi Y, Tobinai K, Takaue Y. 2001. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 28:689-692.
10. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. 2004. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 39:342-348.
11. Kim DH, Kumar D, Messner HA, Minden M, Gupta V, Kuruvilla J, Chae YS, Sohn SK, Lipton JH. 2008. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation. Clin Transplant 22:770-779.
12. Najafzadeh M, Marra CA, Galanis E, Patrick DM. 2009. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 27:991-1004.
13. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL. 2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271-2284.
14. Pellissier JM, Brisson M, Levin MJ. 2007. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 25:8326-8337.
15. Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO. 1982. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 61:310-316.
16. Rothberg MB, Virapongse A, Smith KJ. 2007. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 44:1280-1288.
17. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN. 2007. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain 23:490-496.
18. Sempere A, Sanz GF, Senent L, de la Rubia J, Jarque I, Lopez F, Arilla MJ, Guinot M, Martin G, Martinez J, Marty ML, Sanz MA. 1992. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 10:495-498.
19. Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA. 2012. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: A retrospective analysis of 100 patients. J Support Oncol 10:155-159.
20. Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. 2011. Herpes zoster in Germany: Quantifying the burden of disease. BMC Infect Dis 11:173.